Check the product and lot
The voluntary US recall concerns 200 mg/mL, 10 mL multidose vials intended for subcutaneous use. Greenwich Rx reports two patients receiving emergency-department care after intravenous administration; this product was not formulated for that route.
The company advises affected-lot customers to stop use and follow its disposal directions. Check the linked lot table; discuss health concerns with a healthcare provider.
Attribution and limits
Greenwich Rx has a commercial interest. FDA hosts the company's announcement without endorsement. Grade A denotes a documented recall, not confirmed causation. Reviewed October 2, 2026.
Older context, not the same incident
FDA's August 27 warning explains why supplement-grade glutathione is unsuitable for injectable compounding. That earlier episode names Medisca lot 229536. Neither source establishes a connection between that lot and this Greenwich recall; do not combine their patient counts.
Open the source file
These links support the claims above. Source dates, disclosures and limits are documented in the article and source list.
- FDA — Greenwich Rx company recall and complete lot table (opens in a new tab)October 1, 2026
- FDA — earlier warning on supplement-grade glutathione in injectables (opens in a new tab)August 27, 2026; separate background